Quince Therapeutics Inc.’s mid-July completion of enrollment in the pivotal phase III study in ataxia-telangiectasia (A-T) marked an important milestone for the South San Francisco-based firm, which is not the only contender in the space. The study called NEAT – a rough acronym for “Neurological Effects of eDSP on Subjects with A-T” – will evaluate Quince’s lead asset, eDSP, in the neurodegenerative illness. Read More
Taking weight off with a glucagon-like peptide-1 (GLP-1) receptor agonist and keeping it off once the drug has been discontinued has been a tall order but Response Pharmaceuticals Inc. is seeing progress. Top-line results from its randomized, double-blind, placebo-controlled, parallel-group phase II study of RDX-002, in those who had already wrapped up a GLP-1 receptor agonist course for reducing obesity, were positive. Read More
The increasing recognition of its importance in national security, economic growth and health has seen biotech emerging as the latest frontier in geopolitical competition, with implications for companies ranging from startups to multinationals – and for global investment in the sector. Read More
Daewoong Pharmaceutical Co. Ltd. and Daewoong Therapeutics Inc. reported that their self-developed microneedle patch loaded with semaglutide demonstrated 80% relative bioavailability compared to an injectable subcutaneous formulation of semaglutide in a pilot human pharmacokinetic study. That far exceeds rates seen in other patches or oral formulations. Read More
Doing his version of the Texas Two-Step, Texas Attorney General (AG) Ken Paxton is again shuffling Eli Lilly and Co. into a state courtroom – this time for allegedly overstepping the anti-kickback line. Read More
New hires and promotions in the biopharma industry, including: Akamis, Artios, Biofrontera, Diakonos, Eureka, Gyre, Metagenomi, Polypid, Rezo, X4. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aprea, Elicio, Merck, Nodthera, Novartis, Pfizer. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ADC, Amphastar, Anji, Bridgebio, Handa, Kancera, Nanopalm, Rakovina, Recardio, Xspray. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aavantgarde. Read More
